Literature DB >> 15605079

Chloroquine-induced lipidosis mimicking Fabry disease.

Diana Albay1, Sharon G Adler, Jaya Philipose, C C Calescibetta, Stephen G Romansky, Arthur H Cohen.   

Abstract

Intracellular accumulation of phospholipids may be a consequence of inherited or acquired metabolic disorders. In Fabry disease, deficiency of alpha-galactosidase A results in storage of globotriasylceramide in numerous cells including endothelium, striated muscle (skeletal, cardiac), smooth muscle, and renal epithelium among others; the ultrastructural appearance of the inclusions is of whorled layers of alternating dense and pale material ('zebra bodies' or myeline figures). Chloroquine therapy may result in storage of biochemically and ultrastructurally similar inclusions in many of the same cells as Fabry disease and often results in similar clinical manifestations. We report a 56-year-old woman with rheumatoid arthritis treated with chloroquine, who developed muscle weakness and renal insufficiency; information regarding therapy was not emphasized at the time of renal biopsy, leading to initial erroneous interpretation of Fabry disease. Following muscle biopsy, genetic and enzyme evaluation, and additional studies on the kidney biopsy, a diagnosis of chloroquine toxicity was established. One year following cessation of chloroquine, renal and muscle dysfunction greatly improved. In chloroquine toxicity, inclusions in glomeruli are not only in visceral epithelial, endothelial and mesangial cells but are in infiltrating monocytes/macrophages, which are most commonly present in the mesangium. Curvilinear bodies, the ultrastructural features of chloroquine toxicity in striated muscle, are not present in renal cells. This report documents differences in appearance, cells affected and morphological differential diagnostic features to distinguish these two entities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15605079     DOI: 10.1038/modpathol.3800344

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  15 in total

1.  Hydroxychloroquine-induced podocytopathy mimicking Fabry disease.

Authors:  Justine Serre; David Buob; Jean-Jacques Boffa
Journal:  BMJ Case Rep       Date:  2019-05-13

Review 2.  Lysosomal storage diseases.

Authors:  Carlos R Ferreira; William A Gahl
Journal:  Transl Sci Rare Dis       Date:  2017-05-25

Review 3.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

4.  A renal variant of Fabry disease: A case with a novel Gal A hemizygote mutation.

Authors:  Jorge H Mukdsi; Silvina Gutiérrez; Belén Barrón; Pablo Novoa; Segundo Fernández; Ana B de Diller; Alicia I Torres; Richard N Formica; Marcelo Orías
Journal:  J Nephropathol       Date:  2012-10-01

Review 5.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

6.  Renal phospholipidosis possibly induced by ranolazine.

Authors:  Christoph Scheurle; Maximilian Dämmrich; Jan U Becker; Martin W Baumgärtel
Journal:  Clin Kidney J       Date:  2013-12-10

7.  Curvilinear bodies in hydroxychloroquine-induced renal phospholipidosis resembling Fabry disease.

Authors:  Rui M Costa; Eduardo V Martul; Juan M Reboredo; Secundino Cigarrán
Journal:  Clin Kidney J       Date:  2013-08-13

8.  Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body.

Authors:  Masayoshi Oikawa; Nobuo Sakamoto; Atsushi Kobayashi; Satoshi Suzuki; Akiomi Yoshihisa; Takayoshi Yamaki; Kazuhiko Nakazato; Hitoshi Suzuki; Shu-Ichi Saitoh; Yuichirou Kiko; Hajime Nakano; Takeharu Hayashi; Akinori Kimura; Yasuchika Takeishi
Journal:  BMC Cardiovasc Disord       Date:  2016-05-10       Impact factor: 2.298

9.  Antimalarial drug and renal toxicity.

Authors:  Viroj Wiwanitkit
Journal:  J Nephropharmacol       Date:  2015-12-23

10.  Alterations in endo-lysosomal function induce similar hepatic lipid profiles in rodent models of drug-induced phospholipidosis and Sandhoff disease.

Authors:  Emmanuelle Lecommandeur; David Baker; Timothy M Cox; Andrew W Nicholls; Julian L Griffin
Journal:  J Lipid Res       Date:  2017-04-04       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.